SynthesisFrontiers in oncology2024
Prognostic role of systemic inflammation response index (SIRI) in patients with pancreatic cancer: a meta-analysis.
Synthesis in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of systemic inflammatory response index in patients with bladder cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic value of systemic inflammation response index in patients with glioma: a meta-analysis.Frontiers in immunology · 2025Pooled it
- Systemic Inflammation Response Index (SIRI) and Aggregate Index of Systemic Inflammation (AISI) as Predictors of Mortality in Patients with Upper Gastrointestinal Bleeding.Journal of clinical medicine · 2026Article
- Specific diagnostic value of systemic immune-inflammation indices combined with nutritional and tumor markers in the stage diagnosis of pancreatic cancer: a retrospective cohort study.Frontiers in oncology · 2026Article
- A novel nomogram incorporating preoperative systemic inflammatory response index and clinicopathological parameters for predicting lymph node metastasis in endometrial cancer.Frontiers in oncology · 2026Article
- Predictive value of systemic inflammatory response index for the occurrence and prognosis of lung metastases in papillary thyroid carcinoma.American journal of translational research · 2026Article
- Systemic immuno-metabolic inflammatory indices (neutrophil-to-HDL cholesterol ratio and systemic inflammation response index) are strongly associated with metabolic dysfunction-associated steatotic liver disease: a propensity score-matched study.Frontiers in immunology · 2026Article
- Comparison of pre-treatment systemic inflammation indices (systemic immune-inflammation index, systemic inflammation response index, and inflammatory benchmark index) in predicting mortality risk in patients with pancreatic cancer.Contemporary oncology (Poznan, Poland) · 2026Article
- Complete Pathological Response to Neoadjuvant Treatment in Pancreatic Ductal Adenocarcinoma-Can We Achieve a Long-Term Survival? A Narrative Review.Life (Basel, Switzerland) · 2025Review
- Article
- Systemic inflammatory response index and In-hospital mortality in diabetic heart failure patients: evidence from MIMIC-IV.BMC cardiovascular disorders · 2025Article
- Inflammation, Immunosuppression, and Immunotherapy in Pancreatic Cancer-Where Are We Now?Cancers · 2025Review
- Predictive Value of Inflammation Markers for Frailty in Older Patients with CVD.Clinical interventions in aging · 2025Article
- Development of a Nomogram Integrating Modified Inflammation-Based Indexes for Predicting Overall Survival in Pancreatic Cancer: A Retrospective Study.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The significance of the systemic inflammation response index (SIRI) in predicting the prognosis of patients with pancreatic cancer (PC) has been extensively explored; however, findings remain controversial. As such, this meta-analysis was performed to more precisely determine the utility of the SIRI in predicting PC prognosis. Methods: A comprehensive literature search of the PubMed, Web of Science, Embase, and Cochrane Library databases for relevant studies, published up to June 25, 2024, was performed. The primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS), respectively. The prognostic utility of the SIRI in predicting PC prognosis was estimated by calculating pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Results: Seven studies comprising 1160 patients were included in the present meta-analysis. Pooled findings revealed that elevated SIRI was as a prominent prognostic marker of OS (HR 2.40 [95% CI 1.88-3.05]; p<0.001) and PFS (HR 1.95 [95% CI 1.19-3.21]; p=0.008) in patients diagnosed with PC. According to subgroup analysis, the SIRI remained an outstanding prognostic marker for OS, irrespective of region, sample size, study center, study design, TNM stage, cancer type, cut-off value, treatment, or survival analysis type (all p<0.05). Moreover, based on subgroup analysis, the SIRI demonstrated significant utility in predicting PFS, irrespective of region and threshold value (p<0.05). Conclusion: Results of the present meta-analysis revealed that an increased SIRI significantly predicted OS and PFS in patients diagnosed with PC. Considering its cost-effectiveness and availability, the SIRI may be a promising biomarker for predicting prognosis in patients with PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.